Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells.

Cancer research - 1 Dec 2000

Simonova M, Wall A, Weissleder R, Bogdanov A

Abstract excerpt

Tyrosinase has been suggested as a prodrug-converting enzyme for the treatment of melanoma. We hypothesized that tyrosinase expression in transfected nonmelanotic cells can be used in a gene therapy paradigm of prodrug activation. To verify our hypothesis, we used the following tyrosinase variants: (a) a full-length human tyrosinase clone (T); (b) a mutant lacking the COOH-terminal cytoplasmic domain (TdeltaC);...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Adenocarcinoma
Share to Biotransformation
Share to Fibrosarcoma

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Kidney

Share to Melanins

Share to Monophenol Monooxygenase

Share to Phenols

Share to Prodrugs

Source

Identifiers

PMID: 11118049

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Tyrosinase mutants are capable of prodrug activation in transfected nonmelanotic cells.PMID 11118049Read ↗

Analyses of melanoma-targeted oncolytic adenoviruses with tyrosinase enhancer/promoter-driven E1A, E4, or both in submerged cells and organotypic culturesSemantic proximity Read ↗

Inhibition of tumor growth by polyarginine-fused mutant cytosine deaminase.Semantic proximity Read ↗

Catalytic activity of anin vivo tumor targeted anti-CEA scFv::carboxypeptidase G2 fusion proteinSemantic proximity Read ↗

Designer gene therapy using an Escherichia coli purine nucleoside phosphorylase/prodrug system.Semantic proximity Read ↗

Humanized ADEPT comprised of an engineered human purine nucleoside phosphorylase and a tumor targeting peptide for treatment of cancer.Semantic proximity Read ↗

Genetic Prodrug Activation Therapy for Breast Cancer: A Phase I Clinical Trial oferbB-2–Directed Suicide Gene ExpressionSemantic proximity Read ↗

Polyethylene-glycol-mediated delivery of liposome-entrapped pigments into fibroblasts: experimental pigment cells as models for mutator phenotypes.Semantic proximity Read ↗

Host-cell Interactions of Engineered T cell MicropharmaciesSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.